Concentration of circulating miRNA-containing particles in serum enhances miRNA detection and reflects CRC tissue-related deregulations
Metrics: PDF 949 views | HTML 1816 views | ?
Abdou ElSharawy1,6, Christian Röder2, Thomas Becker3, Jens K. Habermann4, Stefan Schreiber1,5, Philip Rosenstiel1, Holger Kalthoff2
1Institute of Clinical Molecular Biology, Christian-Albrechts-University, Kiel, Germany
2Institute for Experimental Cancer Research, Christian-Albrechts-University, Kiel, Germany
3Department of General Surgery, Visceral, Thoracic, Transplantation and Pediatric Surgery, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
4Section for Translational Surgical Oncology and Biobanking, Department of Surgery, University of Lübeck and University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
5Clinic for Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
6Faculty of Sciences, Division of Biochemistry, Department of Chemistry, Damietta University, New Damietta City, Egypt
Abdou Elsharawy, email: firstname.lastname@example.org
Keywords: serum biomarker, extracellular microvesicles, miRNA-containing particles, colorectal neoplasms and inflammatory bowel disease, strand-specific miRNA deregulation
Received: February 08, 2016 Accepted: September 12, 2016 Published: September 23, 2016
The emerging potential of miRNAs as biomarkers for cancer detection demands parallel evaluation of strategies for reliable identification of disease-related signatures from easily accessible and pertinent body compartments. Here, we addressed whether efficient concentration of circulating miRNA-carrying particles is a rationale for miRNA biomarker discovery. We systematically compared miRNA signatures in 93 RNA preparations from three serum entities (whole serum, particle-concentrated, and particle-depleted fractions) and corresponding tissue samples from patients with colorectal cancer (CRC) as a model disease. Significant differences between whole sera and particle-concentrated serum fractions of CRC patients emerged for 45 of 742 tested miRNAs. Twenty-eight of these 45 miRNAs were differentially expressed between particle-concentrated serum fractions of metastatic CRC- and healthy individuals. Over half of these candidates (15 of 28) showed deregulations only in concentrated serum fractions, but not in whole sera, compared to the respective controls.
Our results also provided evidence of a consistent downregulation of miR-486 and miR-92a, and further showed a possible “strand-specific” deregulation of extracellular miRNAs in CRC. More importantly, most of the identified miRNAs in the enriched sera reflected the patterns of the corresponding tumor tissues and showed links to cancer-related inflammation. Further investigation of seven serum pools revealed a subset of potential extracellular miRNA candidates to be implicated in both neoplastic and inflammatory bowel disease.
Our findings demonstrate that enrichment and sensitive detection of miRNA carriers is a promising approach to detect CRC-related pathological changes in liquid biopsies, and has potential for clinical diagnostics.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.